Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Skip the sketchy online shortcuts
Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
Acknowledgments The work is supported by the National Heart, Lung, and Blood Institute Grant (R01 HL089405) and American Heart Association-National center (0735458 N) to TCZ
Miller NR, Arnold AC
US$ 26.35
US$ 21.74
US$ 23.22
US$ 20.08
US$ 29.60
